MedTrace Logo

Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms

NCT02415010 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2019-12-12

No results posted yet for this study

Summary

The objective of this Post-Market Clinical Follow-up (PMCF) is to confirm the performance and safety of the Codman Enterprise® 2 when used in conjunction with endovascular coil embolization of ruptured or non-ruptured intracranial aneurysms.

Conditions

  • Intracranial Aneurysm

Interventions

DEVICE

Enterprise 2 Vascular Reconstruction Device

Stenting Assisted coiling procedure

Sponsors & Collaborators

  • Cerenovus, Part of DePuy Synthes Products, Inc.

    lead INDUSTRY

Principal Investigators

  • J FIEHLER, MD-PhD · Universitätsklinikum Hamburg-Eppendorf

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2019-06-25
Completion
2019-06-25

Countries

  • Germany
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02415010 on ClinicalTrials.gov